Figure 1

Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection

L Anri Lemoine and Marisel Segarra-Newnham*

Published: 13 November, 2019 | Volume 3 - Issue 1 | Pages: 027-030

acgh-aid1011-g001

Figure 1:

Flow chart for inclusion criteria. LDV/SOF = ledipasvir/sofobuvir; GLE/PIB = glecaprevir/pibrentasvir.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001011 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More